Literature DB >> 19174100

[Clostridium-difficile-associated diarrhea].

Luis Bujanda1, Angel Cosme.   

Abstract

Clostridium difficile is the most frequent cause of nosocomial diarrhea and is a significant cause of morbidity among hospitalized patients. The inflammation is produced as a result of a non-specific response to toxins. In the last few years, a hypervirulent strain, NAP1/BI/027, has been reported. Symptoms usually consist of abdominal pain and diarrhea. The diagnosis should be suspected in any patient who develops diarrhea during antibiotic therapy or 6-8 weeks after treatment. Diagnosis should be confirmed by the detection of CD toxin in stool and by colonoscopy in special situations. The treatment of choice is metronidazole or vancomycin. In some patients who do not respond to this therapy or who have complications, subtotal colectomy may be required. Relapse is frequent and must be distinguished from reinfection. Prevention and control in healthcare settings requires careful attention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19174100     DOI: 10.1016/j.gastrohep.2008.02.003

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  4 in total

1.  Age and gender differences in Clostridium difficile-related hospitalization trends in Madrid (Spain) over a 12-year period.

Authors:  M D Esteban-Vasallo; S Naval Pellicer; M F Domínguez-Berjón; M Cantero Caballero; Á Asensio; G Saravia; J Astray-Mochales
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-07       Impact factor: 3.267

2.  Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole.

Authors:  Annamaria Buschini; Lisa Ferrarini; Susanna Franzoni; Serena Galati; Mirca Lazzaretti; Francesca Mussi; Cristina Northfleet de Albuquerque; Tânia Maria Araújo Domingues Zucchi; Paola Poli
Journal:  J Parasitol Res       Date:  2009-10-21

3.  Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.

Authors:  C Rubio-Terrés; J Cobo Reinoso; S Grau Cerrato; J Mensa Pueyo; M Salavert Lletí; A Toledo; P Anguita; D Rubio-Rodríguez; M Watt; R Gani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-25       Impact factor: 3.267

4.  Traditional Chinese Medicine QPYF as Preventive Treatment for Clostridium difficile Associated Diarrhea in a Mouse Model.

Authors:  Guo Ya-Nan; Wang Jun; Zhang Hao-Jun; Jia Hong-Bing; Li Ping; Liu Xin-Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2016-11-24       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.